PepGen Inc PEPG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PEPG is a good fit for your portfolio.
News
-
PepGen to Participate in Upcoming Investor Conferences
-
PepGen's Rare Muscle Disorder Therapy Gets FDA Orphan Drug, Rare Pediatric Disease Designations
-
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
-
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
-
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
-
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
-
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
-
FDA Lifts Hold on PepGen's New Drug Application for Dystrophy Treatment
Trading Information
- Previous Close Price
- $12.28
- Day Range
- $12.10–13.94
- 52-Week Range
- $3.72–17.51
- Bid/Ask
- $13.40 / $13.90
- Market Cap
- $449.73 Mil
- Volume/Avg
- 146,559 / 113,763
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 64
- Website
- https://www.pepgen.com
Comparables
Valuation
|
Metric
|
PEPG
|
TRDA
|
DYN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 116.50 | — |
Price/Book Value | 2.70 | 1.82 | 17.04 |
Price/Sales | — | 3.38 | — |
Price/Cash Flow | — | 125.17 | — |
Price/Earnings
PEPG
TRDA
DYN
Financial Strength
|
Metric
|
PEPG
|
TRDA
|
DYN
|
|---|---|---|---|
Quick Ratio | 6.30 | 2.25 | 2.41 |
Current Ratio | 6.43 | 2.33 | 2.53 |
Interest Coverage | — | — | — |
Quick Ratio
PEPG
TRDA
DYN
Profitability
|
Metric
|
PEPG
|
TRDA
|
DYN
|
|---|---|---|---|
Return on Assets (Normalized) | −40.24% | 0.84% | −88.69% |
Return on Equity (Normalized) | −50.31% | 1.61% | −114.25% |
Return on Invested Capital (Normalized) | −46.81% | −3.00% | −102.56% |
Return on Assets
PEPG
TRDA
DYN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fljnbmld | Swhjj | $578.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Clhnpfc | Fvdhr | $101.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Blmbnrlw | Jtyyjr | $98.1 Bil | |
MRNA
| Moderna Inc | Xmjcdhbsv | Vrnbz | $42.2 Bil | |
ARGX
| argenx SE ADR | Dggmyrdx | Vblym | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ngqhmtxqw | Tqr | $21.4 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lglqkfp | Qysmcz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ptwvwymt | Tkzfh | $15.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ztgfmtcvpn | Sbqvc | $12.5 Bil | |
INCY
| Incyte Corp | Jmrqmfkr | Gycscl | $11.7 Bil |